Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease cystic fibrosis
Symptom C0004031|allergic bronchopulmonary aspergillosis
Sentences 20
PubMedID- 23278646 Hla-drb1 and hla-dqb1 genes on susceptibility to and protection from allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 25150265 Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 25705310 allergic bronchopulmonary aspergillosis in patient with cystic fibrosis - a case report.
PubMedID- 23278535 Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease.
PubMedID- 25015245 Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 25010610 Anti ige antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
PubMedID- 24043500 Objectives: to evaluate the efficacy and adverse effects of anti-ige therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 20127304 Typical acute complications are infective exacerbations - the most frequent cause of death in cystic fibrosis - along with allergic bronchopulmonary aspergillosis, haemoptyses and pneumothoraces.
PubMedID- 24167019 Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.
PubMedID- 22608296 Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens.
PubMedID- 25431975 Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 25354514 allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated.
PubMedID- 22731696 It is conceivable that high il-10 levels could contribute to the resolution of the aspergillus induced pulmonary inflammation, but high il-10 concentrations have also been associated with development of invasive aspergillosis in non-neutropenic immunocompromised patients and with colonization with a. fumigatus and allergic bronchopulmonary aspergillosis in patients with cystic fibrosis .
PubMedID- 26003072 The classic diagnostic criteria of allergic bronchopulmonary aspergillosis in cystic fibrosis have been established during the cystic fibrosis foundation conference in 2001.
PubMedID- 20714107 Vitamin d3 attenuates th2 responses to aspergillus fumigatus mounted by cd4+ t cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis.
PubMedID- 26187954 allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated.
PubMedID- 22696329 Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 21067334 Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art and further challenges.
PubMedID- 21246055 The ubiquitous fungus aspergillus fumigatus is associated with chronic diseases such as invasive pulmonary aspergillosis in immunosuppressed patients and allergic bronchopulmonary aspergillosis (abpa) in patients with cystic fibrosis or severe asthma.
PubMedID- 20597074 Risk factors for aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis.

Page: 1